SureTrader
Home > Boards > US Listed > Biotechs > MannKind Corp. (MNKD)

On Facebook:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
WHS Member Profile
 
Followed By 3
Posts 486
Boards Moderated 0
Alias Born 12/01/15
160x600 placeholder
MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018 GlobeNewswire Inc. - 2/23/2018 8:00:00 AM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/14/2018 6:24:47 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 8:58:40 AM
David Kendall Joins MannKind as Chief Medical Officer GlobeNewswire Inc. - 2/6/2018 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/19/2018 6:53:47 AM
MannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference GlobeNewswire Inc. - 1/16/2018 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/20/2017 4:55:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2017 4:33:36 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 12/6/2017 4:12:18 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/17/2017 5:02:44 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/7/2017 4:15:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2017 4:08:55 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 11/7/2017 4:03:04 PM
MannKind Corporation Reports 2017 Third Quarter Financial Results GlobeNewswire Inc. - 11/7/2017 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/30/2017 4:34:36 PM
MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017 GlobeNewswire Inc. - 10/27/2017 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/23/2017 8:02:37 AM
MannKind Restructures Near-Term Debt Obligations GlobeNewswire Inc. - 10/23/2017 8:00:00 AM
MannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency (ANVISA) GlobeNewswire Inc. - 10/23/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/13/2017 5:04:55 PM
MannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico GlobeNewswire Inc. - 10/12/2017 9:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/11/2017 5:20:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/11/2017 5:10:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/11/2017 8:01:51 AM
MannKind Announces $61 Million Registered Direct Offering of Common Stock GlobeNewswire Inc. - 10/11/2017 12:02:34 AM
WHS   Saturday, 05/20/17 12:14:16 AM
Re: None
Post # of 27685 
On Facebook:

Vdex Diabetes added 4 new photos.
27 mins ·

We are pleased to announce the opening of our new dedicated facility in Canoga Park where previously we had an office share arrangement. With this new medical facility we will be able to deliver a higher standard of care, and better help patients manage their diabetes.

Our experience to date has shown us the need for a new and better approach. Currently, the management of diabetes is based on outdated protocols, resulting in less-than-ideal outcomes. In addition, doctors' facilities simply are not conducive to an effective patient experience with respect to diabetes. Now, with Vdex, patients will have the most up-to-date treatment protocols together with an office experience built around the idea of producing demonstrably better control of blood sugar.

Through the protocols we've established and implemented with our initial group of patients, we've been able to safely lower HBa1c to levels that were previously unattainable. In some cases, we've seen patients reach HbA1c levels that are physiologically non-diabetic, with no increased risk of hypoglycemia. In fact, we've seen hypoglycemic risk fall at the same time as HbA1c is brought down, something most physicians would say is impossible. We have made extensive use of a new medication, Afrezza, and our conclusion is that we can change the diabetes landscape forever through the use of this medication. We are so confident in this medication, that we believe it really should be the first medication for the treatment of diabetes, assuming the patient meets the necessary criteria.
We invite you to our June 1st grand opening event where we will be giving away a 2 week continuous monitoring trial (normal value, more than$500) to three lucky winners. All you have to do is RSVP using the link below with your Name, Email address and Phone number.

Vdex Diabetes
21201 Victory Blvd #265
Canoga Park, CA 91367
vdexopening@vdexdiabetes.com



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist